S100a8/a9, as a biomarker, has been intensively studied for many diseases including inflammatory bowel disease (Pruenster et al., 2016), myocarditis (Müller et al., 2020), rheumatoid arthritis (Frosch et al., 2000; Inciarte-Mundo et al., 2022), cystic fibrosis (Cohen and Larson, 2005), and infections (Fang et al., 2021). This evidence concerns the gene S100A8 and rheumatoid arthritis.